Patents by Inventor Sacha Holland

Sacha Holland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of angiogenesis
    Publication number: 20040053233
    Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.
    Type: Application
    Filed: August 30, 2002
    Publication date: March 18, 2004
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
  • CD43: modulators of mast cell degranulation
    Publication number: 20030027763
    Abstract: The present invention relates to regulation of IgE-receptor-mediated mast cell degranulation. More particularly, the present invention is directed to nucleic acids encoding CD43 (also called leukosialin or leukocyte large sialoglycoprotein), which is involved in modulation of IgE-receptor-mediated mast cell degranulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate IgE-receptor-mediated mast cell degranulation via modulation of CD43 and CD43-related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to diseases such as allergies and asthma.
    Type: Application
    Filed: May 31, 2002
    Publication date: February 6, 2003
    Applicant: Rigel Pharmaceuticals, Incorporated
    Inventors: Mark Bennett, Sacha Holland, Alex Rossi
  • Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
    Publication number: 20020172984
    Abstract: A method of modulating the biological activity of a transmembrane ligand for an Elk-related receptor tyrosine kinase in a cell expressing the transmembrane ligand, comprising forming a complex between a purified and isolated oligomerized Elk-related receptor tyrosine kinase, or an isoform or an extracellular domain of the kinase, and a transmembrane ligand expressed on the cell, thereby affecting a pathway in the cell which is regulated by the transmembrane ligand.
    Type: Application
    Filed: May 3, 2002
    Publication date: November 21, 2002
    Applicant: Mount Sinai Hospital Corporation
    Inventors: Sacha Holland, Geraldine Mbamalu, Tony Pawson
  • Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
    Patent number: 6413730
    Abstract: A method of modulating the biological activity of a transmembrane ligand for an Elk-related receptor tyrosine kinase in a cell expressing the transmembrane ligand, comprising forming a complex between a purified and isolated oligomerized Elk-related receptor tyrosine kinase, or an isoform or an extracellular domain of the kinase, and a transmembrane ligand expressed on the cell, thereby affecting a pathway in the cell which is regulated by the transmembrane ligand.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: July 2, 2002
    Assignee: Mount Sinai Hospital Corporation
    Inventors: Sacha Holland, Geraldine Mbamalu, Tony Pawson